超声对比剂三十年:过去、现在与未来改进的综述
本文回顾了自20世纪60年代观察到心超声检查中微小气泡增强超声现象、到80年代首个超声对比剂问世及后续Definity、Optison、Sonazoid、SonoVue等商用对比剂的发展历程,指出对比特异技术自90年代首个获批对比剂引入后取得显著进步,但同期新发展的临床转化有限,而微泡物理、化学与生物学行为的认识已大幅提升;
要点
- 当前商用超声对比剂包括Definity、Optison、Sonazoid和SonoVue,已在多种标签内和标签外临床适应证中证明成功。
- 对比特异技术在90年代首批对比剂获批后取得显著进步,但同期新发展的成功临床转化有限。
- 对微泡物理、化学和生物学行为的理解已大幅提升。
研究设计与样本
- 综述,检索范围与纳入文献原文未报告。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Initial reports from the 1960s describing the observations of ultrasound contrast enhancement by tiny gaseous bubbles during echocardiographic examinations prompted the development of the first ultrasound contrast agent in the 1980s. Current commercial contrast agents for echography, such as Definity, Optison, Sonazoid and SonoVue, have proven to be successful in a variety of on- and off-label clinical indications. Whereas contrast-specific technology has seen dramatic progress after the introduction of the first approved agents in the 1990s, successful clinical translation of new developments has been limited during the same period, while understanding of microbubble physical, chemical and biologic behavior has improved substantially. It is expected that for a successful development of future opportunities, such as ultrasound molecular imaging and therapeutic applications using microbubbles, new creative developments in microbubble engineering and production dedicated to further optimizing microbubble performance are required, and that they cannot rely on bubble technology developed more than 3 decades ago.
引用
- Frinking P, Segers T, Luan Y, et al. Three Decades of Ultrasound Contrast Agents: A Review of the Past, Present and Future Improvements. Ultrasound Med Biol. 2020. PMID: 31941587. doi:10.1016/j.ultrasmedbio.2019.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。